Highlights
- Successfully completes POC testing for first ever scalable production of ApoTainer™
- Cellect’s ApoTainer™ built to replace complex laboratory procedures for stem cell extraction at a fraction of the time and cost
- Dr. Shai Yarkoni, Cellect CEO commented: “We believe that the expected demand for stem cells as raw material for regenerative medicine will explode over the next five years. Our ApoTainer™ is intended to ensure this demand is met with a cost-effective quality manufacturing of stem cells.”
- The ApoTainer™ is covered by a portfolio of IP including a patent application for apoptotic selection of stem cells using FasL-coated magnetic beads